Unigene to Present at the 17th Annual Drug Delivery Partnerships Meeting

Oral Presentation and Featured Article in Drug Development & Delivery Magazine to Highlight the Strength of Unigene's Peptelligence™ Platform

Feb 07, 2013, 08:33 ET from Unigene Laboratories, Inc.

BOONTON, N.J., Feb. 7, 2013 /PRNewswire/ -- Unigene Laboratories, Inc. (PINK: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its Chief Scientific Officer, Nozer Mehta, Ph.D., will deliver an oral presentation on the value of Unigene's Peptelligence™ platform for oral peptide delivery at the 17th Annual Drug Delivery Partnerships in San Diego, CA.  

Dr. Mehta's presentation, Peptelligence, the Solution to Oral Peptide Delivery, will be delivered on Friday, February 8, 2013 at 12:15 p.m. PT (3:15 p.m. ET) and will provide a technological overview of Unigene's Peptelligence platform and its clinically proven ability to deliver peptide drugs with a highly engineered oral tablet formulation.

In addition to Dr. Mehta's lecture, Unigene's Peptelligence platform will also be the subject of a featured article in the March 2013 issue Drug Development & Delivery, a pre-print of which will be distributed to conference attendees.

Dr. Mehta commented, "Having our Peptelligence platform featured at Drug Delivery Partnerships, the pharmaceutical industry's largest, longest running and most-respected drug delivery conference, is a tremendous achievement for Unigene and continues the momentum from last year's conference when we were recognized with the 2012 Drug Delivery Partnerships Industry Achievement Award."

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence.  Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, including statements relating to the Company's oral presentation on the value of the Company's Peptelligence™ platform for oral peptide delivery on February 8th at the 17th Annual Drug Delivery Partnerships in San Diego, CA, that the Company's platform will be the subject of a featured article in the March 2013 issue of Drug Development & Delivery and Unigene's ability to build a robust portfolio of proprietary partnerships in peptide-based therapeutics based on its Peptelligence™ platform. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors. These known and unknown risk factors include, but are not limited to: the delay in obtaining or the failure to obtain regulatory approvals for our products and the products of our licensees that may generate royalty and milestone payments to us, our ability to achieve product sales and royalties, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies and our ability to enter into favorable new agreements with such companies, our ability to cut expenses and maintain efficiencies, our ability to enter into new financing arrangements,  the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.

For Investors & Media:

Joshua Drumm, Ph.D. / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020


SOURCE Unigene Laboratories, Inc.